ESMO

Chemotherapy De-Escalation Associated With Excellent HR+/HER2+ Breast Cancer Survival

September 15th 2024, 7:30pm

Article

Patients with early breast cancer treated with presurgical endocrine therapy or chemotherapy plus Herceptin and Perjeta followed by response-guided chemotherapy experienced “exceptionally excellent” survival outcomes.

Outcomes, Lymphedema Risk May Be Similar With Hypofractionated Versus Normofractionated Radiation in Early Breast Cancer

September 15th 2024, 7:00pm

Article

Hypofractionated radiation was noninferior to normofractionated radiation in patients with early breast cancer regarding lymphedema risk.

Presurgical Keytruda-Chemo Combo With Postsurgical Keytruda May Improve Survival in Early TNBC

September 15th 2024, 6:25pm

Article

Patients with early triple-negative breast cancer had improved survival outcomes after receiving presurgical Keytruda plus chemotherapy and postsurgical Keytruda.

Antibody-Drug Conjugate Is Tolerable, Active in CLDN6-Positive Solid Tumors Including Ovarian Cancer

September 15th 2024, 5:52pm

Article

Treatment with the antibody-drug conjugate TORL-1-23 was safe and tolerable in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.

Zynyz Plus Chemo Combo Improves Survival in Recurrent/Metastatic SCAC

September 14th 2024, 11:00pm

Article

Adding Zynyz to carboplatin and paclitaxel prolonged survival without progression in chemotherapy-naive recurrent or metastatic squamous cell carcinoma of the anal canal.

TILs May Predict Survival in Early HER2-Positive Breast Cancer Treated With Herceptin

September 14th 2024, 10:22pm

Article

High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or death with Herceptin treatment.

Lenvima Regimen Offers Benefits in Intermediate Stage Liver Cancer

September 14th 2024, 9:51pm

Article

Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial chemoembolization.

Survival, Progression Improves With Xofigo Plus Xtandi for Certain Patients With Prostate Cancer

September 14th 2024, 9:40pm

Article

Patients with metastatic, castration-resistant prostate cancer saw significant benefits from the combination of Xofigo and Xtandi.

Keytruda Plus Chemoradiotherapy May Represent New Standard of Care in Cervical Cancer Subset

September 14th 2024, 9:11pm

Article

Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated with Keytruda plus chemoradiotherapy.

Postsurgical Keytruda Plus Chemo May Benefit Patients With dMMR Endometrial Cancer

September 14th 2024, 8:30pm

Article

Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among patients with high-risk endometrial cancer.